Affymetrix and NimbleGen Systems Enter into Licensing Agreement
October 06 2006 - 7:00AM
Business Wire
Affymetrix Inc. (Nasdaq:AFFX) and NimbleGen Systems Inc. announced
today that NimbleGen has obtained a non-exclusive, worldwide
license to a number of Affymetrix patents covering the manufacture,
use and sales of nucleic acid microarrays and related products and
services in the research field. Financial details of the license
were not disclosed. �This licensing agreement with NimbleGen
follows from a commercial relationship and enables both companies
to better serve customers within the growing microarray market,�
said Alan Sherr, vice president and chief counsel for Licensing at
Affymetrix. �Since the inception of our licensing program,
Affymetrix has�signed many agreements that validate our position
as�the�clear market�innovator and�leader. We look forward to the
continued expansion of this program.� �This license is a
major�milestone in NimbleGen's evolution as a company, and part of
a fundamental expansion of our commercial strategy,� said Stan
Rose, Ph.D.,�president and CEO of NimbleGen. �Our intent is to
expand dramatically�the ability of scientists to access NimbleGen
products and services.� About NimbleGen Systems NimbleGen Systems,
the leading supplier of flexible high-density microarray products
and services, is enabling a new era of High-Definition Genomics.
NimbleGen uniquely produces high-density arrays of isothermal long
oligos that provide superior results for advanced genomic analysis
methods such as CGH, ChIP, microbial Comparative Genome Sequencing,
and expression tiling. NimbleGen's High-Definition Genomics enables
scientists to obtain and integrate complex genomic data sets not
previously accessible, providing a much clearer understanding of
genome structure and function, and how this relates to biology and
medicine. This improved performance is made possible by NimbleGen's
Maskless Array Synthesis (MAS) technology, which uses digital light
processing and rapid, high-yield photochemistry to synthesize
high-density DNA microarrays.�For more information about NimbleGen,
please visit the company�s website at www.nimblegen.com. About
Affymetrix Affymetrix scientists invented the world's first
high-density microarray in 1989 and began selling the first
commercial microarray in 1994. Since then, Affymetrix GeneChip�
technology has become the industry standard in molecular biology
research. Affymetrix technology is used by the world's top
pharmaceutical, diagnostic and biotechnology companies as well as
leading academic, government and not-for-profit research
institutes. More than 1,400 systems have been installed around the
world and more than 7,000 peer-reviewed papers have been published
using the technology. Affymetrix' patented photolithographic
manufacturing process provides the most information capacity
available today on an array, enabling researchers to use a
whole-genome approach to analyzing the relationship between
genetics and health. Affymetrix is headquartered in Santa Clara,
Calif., with manufacturing facilities in Sacramento, Calif., and
Bedford, Mass. The company maintains important sales and marketing
operations in Europe and Asia and has about 1,100 employees
worldwide. For more information about Affymetrix, please visit the
company's website at www.affymetrix.com. All statements in this
press release that are not historical are "forward-looking
statements" within the meaning of Section 21E of the Securities
Exchange Act as amended, including statements regarding Affymetrix'
"expectations," "beliefs," "hopes," "intentions," "strategies," or
the like. Such statements are subject to risks and uncertainties
that could cause actual results to differ materially for Affymetrix
from those projected, including, but not limited to: risks and
uncertainties relating to commercial success of the licensing
agreement with NimbleGen Systems discussed in this press release;
risks of the Company's ability to achieve and sustain higher levels
of revenue, higher gross margins, reduced operating expenses;
uncertainties relating to technological approaches, manufacturing,
product development; personnel retention; uncertainties related to
cost and pricing of Affymetrix products; dependence on
collaborative partners; uncertainties relating to sole source
suppliers; uncertainties relating to FDA and other regulatory
approvals; competition; risks relating to intellectual property of
others and the uncertainties of patent protection and litigation.
These and other risk factors are discussed in Affymetrix' Form
10-K/A for the year ended December 31, 2005, and other SEC reports,
including its Quarterly Reports on Form 10-Q for subsequent
quarterly periods. Affymetrix expressly disclaims any obligation or
undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change
in Affymetrix' expectations with regard thereto or any change in
events, conditions or circumstances on which any such statements
are based. NOTE: Affymetrix, the Affymetrix logo, and GeneChip are
registered trademarks owned or used by Affymetrix Inc. Affymetrix
Inc. (Nasdaq:AFFX) and NimbleGen Systems Inc. announced today that
NimbleGen has obtained a non-exclusive, worldwide license to a
number of Affymetrix patents covering the manufacture, use and
sales of nucleic acid microarrays and related products and services
in the research field. Financial details of the license were not
disclosed. "This licensing agreement with NimbleGen follows from a
commercial relationship and enables both companies to better serve
customers within the growing microarray market," said Alan Sherr,
vice president and chief counsel for Licensing at Affymetrix.
"Since the inception of our licensing program, Affymetrix has
signed many agreements that validate our position as the clear
market innovator and leader. We look forward to the continued
expansion of this program." "This license is a major milestone in
NimbleGen's evolution as a company, and part of a fundamental
expansion of our commercial strategy," said Stan Rose, Ph.D.,
president and CEO of NimbleGen. "Our intent is to expand
dramatically the ability of scientists to access NimbleGen products
and services." About NimbleGen Systems NimbleGen Systems, the
leading supplier of flexible high-density microarray products and
services, is enabling a new era of High-Definition Genomics.
NimbleGen uniquely produces high-density arrays of isothermal long
oligos that provide superior results for advanced genomic analysis
methods such as CGH, ChIP, microbial Comparative Genome Sequencing,
and expression tiling. NimbleGen's High-Definition Genomics enables
scientists to obtain and integrate complex genomic data sets not
previously accessible, providing a much clearer understanding of
genome structure and function, and how this relates to biology and
medicine. This improved performance is made possible by NimbleGen's
Maskless Array Synthesis (MAS) technology, which uses digital light
processing and rapid, high-yield photochemistry to synthesize
high-density DNA microarrays. For more information about NimbleGen,
please visit the company's website at www.nimblegen.com. About
Affymetrix Affymetrix scientists invented the world's first
high-density microarray in 1989 and began selling the first
commercial microarray in 1994. Since then, Affymetrix GeneChip(R)
technology has become the industry standard in molecular biology
research. Affymetrix technology is used by the world's top
pharmaceutical, diagnostic and biotechnology companies as well as
leading academic, government and not-for-profit research
institutes. More than 1,400 systems have been installed around the
world and more than 7,000 peer-reviewed papers have been published
using the technology. Affymetrix' patented photolithographic
manufacturing process provides the most information capacity
available today on an array, enabling researchers to use a
whole-genome approach to analyzing the relationship between
genetics and health. Affymetrix is headquartered in Santa Clara,
Calif., with manufacturing facilities in Sacramento, Calif., and
Bedford, Mass. The company maintains important sales and marketing
operations in Europe and Asia and has about 1,100 employees
worldwide. For more information about Affymetrix, please visit the
company's website at www.affymetrix.com. All statements in this
press release that are not historical are "forward-looking
statements" within the meaning of Section 21E of the Securities
Exchange Act as amended, including statements regarding Affymetrix'
"expectations," "beliefs," "hopes," "intentions," "strategies," or
the like. Such statements are subject to risks and uncertainties
that could cause actual results to differ materially for Affymetrix
from those projected, including, but not limited to: risks and
uncertainties relating to commercial success of the licensing
agreement with NimbleGen Systems discussed in this press release;
risks of the Company's ability to achieve and sustain higher levels
of revenue, higher gross margins, reduced operating expenses;
uncertainties relating to technological approaches, manufacturing,
product development; personnel retention; uncertainties related to
cost and pricing of Affymetrix products; dependence on
collaborative partners; uncertainties relating to sole source
suppliers; uncertainties relating to FDA and other regulatory
approvals; competition; risks relating to intellectual property of
others and the uncertainties of patent protection and litigation.
These and other risk factors are discussed in Affymetrix' Form
10-K/A for the year ended December 31, 2005, and other SEC reports,
including its Quarterly Reports on Form 10-Q for subsequent
quarterly periods. Affymetrix expressly disclaims any obligation or
undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change
in Affymetrix' expectations with regard thereto or any change in
events, conditions or circumstances on which any such statements
are based. NOTE: Affymetrix, the Affymetrix logo, and GeneChip are
registered trademarks owned or used by Affymetrix Inc.
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Sep 2024 to Oct 2024
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Oct 2023 to Oct 2024